This year, gene-editing technology was customized to fix mutations in a single patient’s genes for the first time.

If you have been wondering whether CRISPR Therapeutics at around $57 a share is a bargain or a bubble, you are not alone. This stock sits at the crossroads of high science and high expectations. The ...

To the research team working to save him, KJ Muldoon was first known only as Patient Eta. But within months, KJ’s name — and ...

According to Precedence Research, the global gRNA market size is expected to grow from USD 708.92 million in 2025 to nearly ...

A team of researchers at the Icahn School of Medicine at Mount Sinai has uncovered why children with the same ...

A Mount Sinai team showed that the same leukemia mutation behaves differently depending on when it arises during development.

Detailed price information for Intellia Thera CS (NTLA-Q) from The Globe and Mail including charting and trades.

A Leicester teen is “really well” after being the first to receive a pioneering blood cancer treatment. Alyssa Tapley was ...

Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced the publication of ...

Cambridge-based Fulcrum Therapeutics said it will aim to launch a large clinical trial in the second half of 2026 to prove ...